Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quintiles Launches Asset Development Planning | Contract Pharma
Breaking News

Quintiles Launches Asset Development Planning

IADP aims to facilitate strategic planning process, data analytics and modeling

Quintiles has launched its Integrated Asset Development Plan (IADP) offering, a suite of services for development, regulatory strategy, market and patient access and commercial services to help facilitate the strategic planning process, data analytics and modeling.
 
“In today’s increasingly complex healthcare market, a successful asset must meet key value objectives and evidence needs for a variety of stakeholders, including patients, providers, regulators and payers,” said Rick Sax, M.D., senior vice president, Quintiles Advisory Services. “A successful asset development plan considers the dynamic requirements of stakeholders to enable better decisions during development. With IADP, we bring an objective view of commercial viability, a structured design process and robust technology to create an approach that helps our customers improve their probability of success.”
 
As part of the IADP offering, Quintiles advises on considerations for an asset’s value proposition, Target Product Profile (TPP), regulatory plan, and a Clinical Development Plan (CDP). The IADP also includes market access planning, evidence generation plan, commercial launch plan, lifecycle management and real-world evidence risk management plans.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters